KPV Peptide: The PepT1 Research Record and Where to Buy It (2026)

Why researchers pay attention

The alpha-MSH fragment took a different path from its parent. A mouse peritonitis study looked at the obvious receptor route and came back with a negative: KPV's anti-migratory activity was not blocked by an MC3/4 receptor antagonist, and the peptide did not raise macrophage cAMP under the conditions tested.

That does not rule out every interaction with a melanocortin receptor. What it means is that the measured activity survived blockade of the pathway everyone would check first, which left the mechanism open until the intestinal-cell work supplied a positive answer.

Identity matters whenever results are compared across studies and lots. The guide to verifying a certificate against its lot covers that check. A related paperwork problem, for a peptide that carries a metal ion, is worked through in the GHK-Cu identity review.

PepT1 carried KPV into two cell types

Dalmasso and colleagues worked with Caco2-BBE intestinal epithelial cells and Jurkat T cells, and found PepT1-mediated KPV uptake in both. During IL-1beta stimulation of the Caco2-BBE cells, co-incubation with 10 nM KPV reduced NF-kappaB reporter activity and shifted I-kappaB-alpha degradation and phosphorylation kinetics. MAP kinase signalling changed as well, and pro-inflammatory cytokine secretion fell. The authors put all of it down to transporter-mediated uptake rather than melanocortin signalling.

Transporter kinetics differed between the two systems. Apparent hPepT1 Km was around 160 micromol/L in Caco2-BBE cells and around 700 micromol/L in Jurkat cells. Those are uptake constants measured in cell models, not a half-life, a bioavailability figure, or an exposure target in a living body. Nothing in this work measured absorption, distribution, metabolism or elimination in people.

Uptake in Jurkat cells widened the finding past the intestinal epithelium without making it tissue-independent, and the 10 nM figure describes a signalling change under IL-1beta stimulation. The work supports a PepT1-linked model in the cells tested. It does not make PepT1 the only route KPV can take in every tissue.

Curo's quality and testing standard sets out the documentation used for catalogue material.

The knockout result puts PepT1 at the center

Mouse protocols took the hypothesis out of the dish. In Dalmasso's DSS- and TNBS-induced colitis experiments the animals drank water containing 100 micromol/L KPV, and inflammatory readouts including colonic cytokine expression came down. KPV on its own changed neither basal colonic myeloperoxidase nor the other inflammatory parameters measured, which is an observation about those particular readouts rather than a safety finding.

A second 2008 paper widened the model set and added another mark against the receptor explanation. Across DSS and CD45RBhi transfer-colitis models, the KPV arm showed reduced histologic inflammation and lower myeloperoxidase activity, and the authors reported effects in mice whose MC1R was non-functional. A melanocortin receptor being out of action did not remove the response.

The delivery work runs alongside the mechanism work. In TNBS-induced ulcerative colitis in rats, a KPV hydrogel administered rectally was reported to reduce symptoms and to improve epithelial-barrier, crypt and goblet-cell morphology. That is a formulation result in a rodent model, and it belongs to the same preclinical tier as everything above it.

The decisive experiment came later, in the AOM/DSS colitis-associated-cancer model. Wild-type and PepT1-knockout mice drank water containing 100 micromol/L KPV through two 7-day DSS cycles. Tumorigenesis-associated endpoints fell in the wild-type animals. In the knockouts the effect was simply absent. A second protocol in the same paper gave APCMin/+ mice that same 100 micromol/L drinking water from 5 to 18 weeks of age.

Take the transporter away and the effect goes with it. That is a different order of evidence from a shifted signalling marker, because it puts PepT1 in a causal position inside the model instead of merely alongside the outcome. The concentrations and schedules belong to those mouse studies and are not a human protocol.

Human studies to date

There are none in the registries. The specified ClinicalTrials.gov searches for KPV and Lys-Pro-Val returned zero registered studies on August 25, 2026.

The one human-tissue experiment on the record is about delivery, not effect. In microporated human skin studied ex vivo, passive KPV permeation stayed below the 0.01 microgram/mL detection limit, microneedle treatment produced 4.4 micrograms per square centimetre per hour, and electrically assisted conditions pushed permeation higher again.

Below a detection limit is not zero. It means passive movement could not be quantified beneath that threshold. The assisted-delivery figures show the method changed transport across excised tissue, and they stop there: no systemic bioavailability percentage, no human half-life, no participant.

Regulatory status in 2026

A Federal Register notice put KPV free base and KPV acetate in front of FDA's Pharmacy Compounding Advisory Committee on July 23, 2026, under docket FDA-2025-N-6895, with wound healing and inflammatory conditions as the evaluated uses.

FDA's staff recommended against listing. The agency's briefing document for KPV reported no human data for products containing either form and unknown potential human safety risks. The committee disagreed. Voting separately on each form, it recommended both for inclusion by 8 in favor to 6 against with one abstention. Hyman, Phelps & McNamara reported the same 8-6-1 result for both forms, and Pharmaceutical Executive and Regulatory Focus reported the tally independently.

The recommendation is advisory. FDA is not bound by it, and a substance reaches the section 503A bulks list through agency rulemaking rather than a committee vote. FDA's meeting page carries the briefing documents, the questions put to the committee and the archived broadcast, but no minutes or vote table, so the tallies rest on contemporaneous reporting.

Is KPV legal to buy?

In the United States, KPV is legal to purchase as a research chemical for laboratory use. It is not a controlled substance and does not appear on any DEA schedule as of August 2026. What it also is not: an approved drug, a dietary supplement ingredient, or a compound cleared for human or veterinary use in any form.

Three boundaries define the current picture:

1. Research sale is lawful; human-use marketing is not. FDA has repeatedly cited peptide sellers whose sites promote human use, and courts have treated that line seriously. The owner of one vendor, Paradigm Peptides, was sentenced to 70 months in federal prison in July 2026 for selling unapproved and adulterated drugs. The offense was not stocking peptides. It was selling them for human consumption while faking the paperwork.
2. The compounding question is open, not settled. The July 2026 advisory vote points toward possible pharmacy compounding for wound healing and inflammatory conditions in the future. Until FDA completes rulemaking, no compounded or prescription form of KPV exists lawfully in the US.
3. Sport rules are separate from law. KPV is not named on the WADA 2026 Prohibited List as of August 2026, but the list's S0 category covers non-approved substances as a class, so tested athletes should treat any unapproved peptide as within scope.

None of this changes how a supplier like Curo operates: KPV is sold strictly for laboratory research, not for human or animal use. Curo's research use only policy covers what that means in practice.

Where to buy KPV for laboratory research

Researchers looking for where to buy KPV face a supplier market that changed sharply in 2025 and 2026. Peptide Sciences closed in March 2026, Amino Asylum went offline after a reported federal raid in June 2025, and Paradigm Peptides ended in a criminal sentencing. Several sites now trade on those dead brand names, so the first check is not price. It is whether the company behind the storefront actually exists. Our guide to the best peptide companies in 2026 covers the current field vendor by vendor.

Five checks separate a documented KPV source from an anonymous one:

1. A lot-specific COA, published before purchase. The certificate should match the exact lot on the vial, not a generic product-page badge. The help center shows how to verify a certificate against your lot.
2. A named, independent laboratory. A COA is only as good as the lab that issued it. Court records in the Paradigm case showed the defendants admitted faking certificates outright, which is the failure mode this check exists to catch.
3. Identity and purity by more than one method. HPLC purity alone leaves an identity gap. KPV has a small mass, 342.43 g/mol, and several near-neighbour tripeptides, so LC-MS identity confirmation matters here more than usual. Look for endotoxin results alongside it.
4. An identifiable company. A legal entity, a real contact route, and consistent policies. A brand name alone is not an identity, and the clone sites trading on dead vendors prove it.
5. Payment with recourse. Card payment carries buyer protection. Venmo, Zelle, and crypto-only checkouts remove it.

Curo stocks KPV 10mg in the research catalog. Every lot is tested by an independent laboratory for identity (LC-MS), purity (HPLC), and endotoxin, the full testing standard is documented, and every certificate is publicly readable without an account. Orders are fulfilled from the United States, catalogue material is supplied for research use only, and payment options include card, crypto, Zelle, and Cash App.

How much does KPV cost?

As of August 2026, research-grade KPV in the 10mg vial size typically runs $55 to $95 from US suppliers that publish lot-matched, independently issued COAs. Cheaper vials exist, some near $30, but they cluster among suppliers with no published lot documentation or with certificates issued offshore against a lot number that never appears on the vial. An unverified lot is unusable as research material at any price. Curo's KPV 10mg is $74, inside that documented tier rather than above it. Compare the documentation attached to the current batch first, then the price. The pre-purchase checklist walks the full sequence.

One KPV-specific caution on price comparison: vial sizes for this compound are not standard across the market. Several suppliers list 5mg and 10mg side by side, and some publish a net-content figure on the COA that differs from the label. Read the certificate's assay content, not the label, before comparing two prices.

What a KPV certificate of analysis should show

KPV is synthesized by many suppliers, so material quality is something a lab confirms rather than assumes. Identity, purity, endotoxin load, and fill accuracy all vary by manufacturer and by lot. A certificate worth relying on shows:

• The exact lot number that appears on the vial.
• The issuing laboratory's name and report identifier.
• HPLC purity with the chromatogram, not a bare percentage.
• Mass-spectrometry identity confirmation against the expected 342.43 g/mol.
• An endotoxin result, since a pure peptide can still carry bacterial contamination from synthesis.
• A way to verify the document independently, through a public lookup or the lab itself. Curo's COA database is open for exactly this reason.

A well-tested lyophilized peptide can still be degraded by poor handling after receipt. See storing research peptides and bacteriostatic water for the storage side.

For a broader framework on separating documentation from marketing when comparing suppliers, see how to evaluate research peptide companies and the companion piece on purity claims and COA batch documentation.

Further reading

BPC-157 sat on the same two-day July 2026 committee agenda and arrives there with a longer human record behind it, though no verifiable controlled trial of it is running.

Semax was reviewed at that same meeting for cerebral ischemia, migraine and trigeminal neuralgia, and its record runs differently again: a long Russian clinical literature and no registered US intervention studies. That contrast is drawn out in the Semax profile.

Frequently asked questions

What is KPV peptide?

KPV is a synthetic tripeptide of lysine, proline and valine, corresponding to residues 11 to 13 of alpha-MSH. It carries CAS number 67727-97-3 and a molecular weight of 342.43 g/mol. It is not approved as a drug anywhere, and in the United States it is sold only as a research chemical for laboratory use.

Is KPV legal to buy in the US?

Yes, as a research chemical for laboratory use. KPV is not a controlled substance as of August 2026 and appears on no DEA schedule. It is not approved for human use, and no lawful compounded form exists, since the July 2026 advisory recommendation still requires FDA rulemaking to take effect.

Where can a researcher buy KPV?

From suppliers that publish lot-specific, independently issued COAs and operate as identifiable companies. Several well-known vendors closed or faced federal action in 2025 and 2026, and clone sites now trade on their names, so verify the company before the price. Curo lists KPV 10mg for laboratory research with every lot's certificate published openly.

How much does KPV cost?

Suppliers that publish lot-matched third-party COAs typically charge $55 to $95 for a 10mg research vial as of August 2026. Curo's 10mg vial is $74 with the lot's certificate published before purchase. Vials near $30 usually come without verifiable lot documentation, and vial sizes vary across the market, so check the COA's assay content before comparing prices.

Does KPV act through melanocortin receptors?

The strongest published experiments support a different route in the systems tested. MC3/4 antagonism did not block the anti-migratory effect in the mouse peritonitis study, Dalmasso attributed the cell effects to PepT1 uptake, and the later knockout experiment made the intestinal effect PepT1-dependent. The results do not establish one exclusive mechanism across every tissue.

What do KPV's apparent Km values mean?

They describe apparent PepT1 uptake kinetics in Caco2-BBE and Jurkat cell models, roughly 160 micromol/L and 700 micromol/L respectively. They are not measures of systemic human exposure, half-life, or bioavailability, and they do not convert into a human protocol.

Has KPV been studied in human participants?

No. The specified ClinicalTrials.gov searches for KPV and Lys-Pro-Val returned zero registered studies on August 25, 2026. The ex vivo skin work used excised human tissue and supplied no participant-level efficacy or safety results.

What did the July 2026 committee decide about KPV?

It recommended both the free base and the acetate for the section 503A bulks list, 8 in favor to 6 against with one abstention on each form, for wound healing and inflammatory conditions. That is a non-binding recommendation to FDA, not an approval and not a listing. FDA staff had recommended against it.

What should a certificate of analysis for KPV show?

Lot-specific identity and purity data from chromatographic and mass-spectrometry methods, plus endotoxin and net-content results, tied to the exact lot number on the vial and verifiable through a public lookup.